However, a subset of patients with specific secondary KIT mutations, such as those in exon 17, appeared to derive more benefit, suggesting that nilotinib may have a role in certain molecular subtypes of GIST. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.